GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ondine Biomedical Inc (LSE:OBI) » Definitions » Shares Outstanding (EOP)

Ondine Biomedical (LSE:OBI) Shares Outstanding (EOP) : 194.98 Mil (As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Ondine Biomedical Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Ondine Biomedical's shares outstanding for the quarter that ended in Jun. 2023 was 194.98 Mil.

Ondine Biomedical's quarterly shares outstanding increased from Dec. 2022 (194.59 Mil) to Jun. 2023 (194.98 Mil). It means Ondine Biomedical issued new shares from Dec. 2022 to Jun. 2023 .

Ondine Biomedical's annual shares outstanding increased from Dec. 2021 (194.59 Mil) to Dec. 2022 (194.59 Mil). It means Ondine Biomedical issued new shares from Dec. 2021 to Dec. 2022 .


Ondine Biomedical Shares Outstanding (EOP) Historical Data

The historical data trend for Ondine Biomedical's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ondine Biomedical Shares Outstanding (EOP) Chart

Ondine Biomedical Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 194.59 194.59 194.59 194.59 194.59

Ondine Biomedical Semi-Annual Data
Dec06 Jun07 Dec07 Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 194.59 194.59 194.59 194.59 194.98

Competitive Comparison of Ondine Biomedical's Shares Outstanding (EOP)

For the Biotechnology subindustry, Ondine Biomedical's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ondine Biomedical's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ondine Biomedical's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Ondine Biomedical's Shares Outstanding (EOP) falls into.



Ondine Biomedical Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Ondine Biomedical  (LSE:OBI) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Ondine Biomedical Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Ondine Biomedical's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Ondine Biomedical (LSE:OBI) Business Description

Traded in Other Exchanges
Address
1100 Melville Street, Suite 888, Vancouver, BC, CAN, V6E4A6
Ondine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportable operating segment that is antimicrobial photodynamic therapy (aPDT) products.

Ondine Biomedical (LSE:OBI) Headlines

No Headlines